Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3434172 in advanced solid tumors
NCT03936959Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of reozalimab in solid tumor (advanced stage), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With Dose Limiting Toxicities. Started May 2019; status: terminated.
02
Drugs
reozalimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03936959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936959.